Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Standardized Dataset of a Spontaneous Adverse Event Reporting System
Mohammad A. Khaleel, Amer Hayat Khan, Siti Maisharah Sheikh Ghadzi, et al.
Healthcare (2022) Vol. 10, Iss. 3, pp. 420-420
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database
Jianxing Zhou, You Zheng, Baohua Xu, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 34
Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase
Junyi Shen, Rong Hu, Anqi Lin, et al.
EClinicalMedicine (2024) Vol. 73, pp. 102684-102684
Open Access | Times Cited: 18
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach
Valentina Giunchi, Michele Fusaroli, Manfred Hauben, et al.
Drug Safety (2023) Vol. 46, Iss. 10, pp. 921-926
Open Access | Times Cited: 24
The evolving role of disproportionality analysis in pharmacovigilance
Michele Fusaroli, Emanuel Raschi, Elisabetta Poluzzi, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 8, pp. 981-994
Closed Access | Times Cited: 14
Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)
Alan Shi, H. Nguyen, Chiaoyun Benson Kuo, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 3, pp. 566-572
Closed Access | Times Cited: 11
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
Michele Fusaroli, Valentina Giunchi, Vera Battini, et al.
Drug Safety (2024) Vol. 47, Iss. 3, pp. 271-284
Open Access | Times Cited: 10
Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database
Robert Morris, Rahinatu Ali, Feng Cheng
Current Drug Targets (2024) Vol. 25, Iss. 7, pp. 454-464
Closed Access | Times Cited: 10
Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
Ruichen Gao, Wenjun Liang, Jintao Chen, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Characteristics of second primary malignancies following bispecific antibodies therapy
Xiaojie Liang, Baiwei Luo, B.Y. Lin, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 4, pp. e011200-e011200
Open Access | Times Cited: 1
Pancreatitis associated with BRAF inhibitors: a disproportionality analysis based on the Food and Drug Administration Adverse Event Reporting System
Shoujun Wang, Jinjing Wang, Huahua Zhang, et al.
International Journal of Clinical Pharmacy (2025)
Closed Access | Times Cited: 1
Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database
Shuang Xia, Hui Gong, Yi‐Chang Zhao, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 1, pp. 211-219
Closed Access | Times Cited: 19
Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study
Britney Stottlemyer, Michael C. McDermott, Mackenzie R. Minogue, et al.
Therapeutic Advances in Drug Safety (2023) Vol. 14
Open Access | Times Cited: 11
RxNorm for drug name normalization: a case study of prescription opioids in the FDA adverse events reporting system
Huyen Le, Ru Chen, Stephen Harris, et al.
Frontiers in Bioinformatics (2024) Vol. 3
Open Access | Times Cited: 4
A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
Yu Lin, Xinlei Zheng, Chen Yan, et al.
Heliyon (2024) Vol. 10, Iss. 6, pp. e27529-e27529
Open Access | Times Cited: 4
Real-world safety evaluation of brivaracetam: insights from the US FDA adverse event reporting system
Zenan Meng, Xinzhi Li, Yue Liao, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Drug-induced dementia: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
Lisi Xu, Ruonan Zhang, Xiaolin Zhang, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access
Diabetic Ketoacidosis and the Use of New Hypoglycemic Groups: Real-World Evidence Utilizing the Food and Drug Administration Adverse Event Reporting System
Hilal Thaibah, Otilia J.F. Banji, David Banji, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 214-214
Open Access
Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database
Pingyun Ding, Qinghua Luo, Liping Cao
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Identifying cardiovascular toxicity associated with sphingosine 1-phosphate receptor modulators: A case-control study based on the FDA adverse event reporting system
Ying Li, Jingmin Zhang, Guangrui Yang, et al.
International Immunopharmacology (2025) Vol. 153, pp. 114520-114520
Closed Access
Deduplicating the FDA adverse event reporting system with a novel application of network-based grouping
Kory Kreimeyer, Jonathan Spiker, Oanh Dang, et al.
Journal of Biomedical Informatics (2025) Vol. 165, pp. 104824-104824
Closed Access
Towards interpretable drug interaction prediction via dual-stage attention and Bayesian calibration with active learning
Rongpei Li, Yufang Zhang, Heqi Sun, et al.
PeerJ Computer Science (2025) Vol. 11, pp. e2847-e2847
Open Access
Way forward to pharmacovigilance and adverse drug reaction monitoring in India: A critical review
Reena Doomra, Deep Inder, Pawan Kumar
Journal of Integrative Medicine and Research (2025) Vol. 3, Iss. 2, pp. 91-96
Closed Access
Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS)
Wenqiang Kong, Wei Mao, Lin Zhang, et al.
Frontiers in Pediatrics (2023) Vol. 10
Open Access | Times Cited: 9
Safety of Dual Orexin Receptor Antagonist Daridorexant: A Disproportionality Analysis of Publicly Available FAERS Data
Giuseppe Cicala, María Antonietta Barbieri, Giulia Russo, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 342-342
Open Access | Times Cited: 3
Profiling the Cardiovascular Toxicities of CDK4/6 Inhibitors: A Real-World Pharmacovigilance Study
Jae Hyun Kim
Cancers (2024) Vol. 16, Iss. 16, pp. 2869-2869
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top